Arrowhead Research | ARWR - Operating Expenses


Arrowhead Research reported $245.35M in Operating Expenses for its fiscal quarter ending in June of 2026.





Operating Expenses Change Date
Agios Pharmaceuticals USD 130.77M 10.77M Mar/2026
Alnylam Pharmaceuticals USD 1.06B 160.97M Jun/2026
Anika Therapeutics USD 137.28M 3.38M Jun/2026
Arrowhead Research USD 245.35M 30.35M Jun/2026
Heron Therapeutics USD 40.55M 1.46M Dec/2025
Incyte USD 973.64M 4.65B Jun/2026
Ionis Pharmaceuticals USD 370.24M 6.24M Jun/2026
Ligand Pharmaceuticals USD 55.1M 20.75M Jun/2026
Merck USD 15.77B 2.4B Jun/2026
Moderna USD 960M 817M Jun/2026
Nektar Therapeutics USD 49.12M 8.22M Mar/2026
Novartis USD 10.2B 912M Jun/2026
Sarepta Therapeutics USD 387.96M 15.59M Jun/2026
TG Therapeutics USD 218.66M 48.54M Jun/2026
Ultragenyx Pharmaceutical USD 289M 16M Jun/2026
Vertex Pharmaceuticals USD 2.07B 217.1M Jun/2026
Xencor USD 87.82M 5.44M Jun/2026